Suzuki K, Itaya S, Tsuge I, Matsuda T, Motai H, Kobayashi T, Shimada J, Baba S
Dept. of Otolaryngology, Nagoya City University Medical School.
Gan To Kagaku Ryoho. 1993 Aug;20(10):1349-54.
Concentrations of Tegafur, 5-FU, and Uracil were measured in the tissues and serum of 32 patients with malignant head and neck tumors after administration of UFT or UFT and OK-432. Of the 32 patients, 15 patients were treated with UFT alone and 17 patients with a combination of UFT and a clinical dose of OK-432. The level of 5-FU was higher in the tissues and serum in the patients who received the combined administration of UFT and OK-432 than in those the received UFT alone. In particular, levels of 5-FU in tumor tissue and metastatic lymph node tissue were higher than 0.05 micrograms/g even 14.6 hours after the last administration of UFT. No significant undesirable interactions between UFT and OK-432 were exhibited during combination therapy of these agents in clinically administered doses. From our satisfactory results, clinical cures would be expected by the combined immuno-chemotherapeutic action of these agents.
在32例恶性头颈部肿瘤患者给予优福定（UFT）或优福定联合沙培林（OK - 432）后，测定其组织和血清中的替加氟、5-氟尿嘧啶（5-FU）和尿嘧啶浓度。32例患者中，15例仅接受优福定治疗，17例接受优福定与临床剂量沙培林联合治疗。接受优福定与沙培林联合给药的患者，其组织和血清中的5-FU水平高于仅接受优福定治疗的患者。特别是，即使在最后一次给予优福定14.6小时后，肿瘤组织和转移淋巴结组织中的5-FU水平仍高于0.05微克/克。在这些药物以临床给药剂量联合治疗期间，未显示出优福定与沙培林之间有明显的不良相互作用。基于我们满意的结果，预计通过这些药物的联合免疫化疗作用可实现临床治愈。
